RZLT Key Statistics, Chart & Performance
The current stock price of RZLT is 1.77 USD. In the past month the price decreased by -81.66%. In the past year, price decreased by -59.68%.
RZLT Latest News, Press Relases and Analysis
RZLT Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24 | 400.88B | ||
| AMGN | AMGEN INC | 14.97 | 176.29B | ||
| GILD | GILEAD SCIENCES INC | 15.18 | 154.20B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.28 | 115.75B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.06 | 80.71B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 784.76 | 52.87B | ||
| INSM | INSMED INC | N/A | 37.29B | ||
| NTRA | NATERA INC | N/A | 32.01B | ||
| BIIB | BIOGEN INC | 10.44 | 25.64B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.6 | 22.27B | ||
| INCY | INCYTE CORP | 16 | 20.16B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.32B |
Related stock screener links
About RZLT
Company Profile
Rezolute, Inc. operates as a biopharmaceutical company, which engages in the development of drug therapies for patients with metabolic and orphan diseases. The company is headquartered in Redwood City, California and currently employs 71 full-time employees. The company went IPO on 2011-12-23. Its lead clinical asset, Ersodetug (formerly RZ358), is a potential treatment for hypoglycemia caused by multiple forms of hyperinsulinism including congenital HI and tumor HI. Ersodetug is an intravenously administered human monoclonal antibody that binds to a unique site (allosteric) on the insulin receptor in insulin target tissues, such as in the liver, fat, and muscle. Congenital is a rare pediatric genetic disorder characterized by excessive production of insulin by the pancreas. RZ402, which is an oral plasma kallikrein inhibitor (PKI) being developed as a potential therapy for the chronic treatment of diabetic macular edema (DME). DME is a vascular complication of diabetes and a leading cause of blindness. RZ402 is designed to block bradykinin production and its resulting effects on vascular leakage and inflammation.
Company Info
REZOLUTE INC
275 Shoreline Drive, Suite 500
Redwood City CALIFORNIA 94065 US
CEO: Nevan Elam
Employees: 71
Phone: 16502064507
REZOLUTE INC / RZLT FAQ
What does RZLT do?
Rezolute, Inc. operates as a biopharmaceutical company, which engages in the development of drug therapies for patients with metabolic and orphan diseases. The company is headquartered in Redwood City, California and currently employs 71 full-time employees. The company went IPO on 2011-12-23. Its lead clinical asset, Ersodetug (formerly RZ358), is a potential treatment for hypoglycemia caused by multiple forms of hyperinsulinism including congenital HI and tumor HI. Ersodetug is an intravenously administered human monoclonal antibody that binds to a unique site (allosteric) on the insulin receptor in insulin target tissues, such as in the liver, fat, and muscle. Congenital is a rare pediatric genetic disorder characterized by excessive production of insulin by the pancreas. RZ402, which is an oral plasma kallikrein inhibitor (PKI) being developed as a potential therapy for the chronic treatment of diabetic macular edema (DME). DME is a vascular complication of diabetes and a leading cause of blindness. RZ402 is designed to block bradykinin production and its resulting effects on vascular leakage and inflammation.
What is the current price of RZLT stock?
The current stock price of RZLT is 1.77 USD. The price decreased by -4.32% in the last trading session.
Does RZLT stock pay dividends?
RZLT does not pay a dividend.
What is the ChartMill rating of REZOLUTE INC stock?
RZLT has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What is the analyst forecast for RZLT stock?
16 analysts have analysed RZLT and the average price target is 16.09 USD. This implies a price increase of 809.23% is expected in the next year compared to the current price of 1.77.
Who owns REZOLUTE INC?
You can find the ownership structure of REZOLUTE INC (RZLT) on the Ownership tab.
RZLT Technical Analysis
RZLT Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to RZLT. No worries on liquidiy or solvency for RZLT as it has an excellent financial health rating, but there are worries on the profitability.
RZLT Financial Highlights
Over the last trailing twelve months RZLT reported a non-GAAP Earnings per Share(EPS) of -0.93. The EPS increased by 26.77% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -48.82% | ||
| ROE | -52.63% | ||
| Debt/Equity | 0 |
RZLT Forecast & Estimates
16 analysts have analysed RZLT and the average price target is 16.09 USD. This implies a price increase of 809.23% is expected in the next year compared to the current price of 1.77.